Cathie Wood Sells $5.2 Million in AI Stock; Discover What Ark Invest Acquired in Its Place
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Updated: Sep 24 20250mins
Ark Invest's Sale of Tempus AI Shares: Ark Invest, led by Cathie Wood, sold 62,352 shares of Tempus AI Inc for approximately $5.2 million, despite the company recently receiving FDA clearance for its RNA-based diagnostic device.
Recent Trading Activity: The firm has been reducing its position in Tempus AI over the past few weeks, having sold shares worth $3.76 million and $2.1 million in earlier transactions, while also making other trades in companies like Arcturus Therapeutics and Roku.
TEM.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 90.18 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 74.910
Low
80.00
Averages
90.18
High
105.00
Current: 74.910
Low
80.00
Averages
90.18
High
105.00
BTIG
Mark Massaro
Buy
maintain
$96 -> $105
2025-11-25
Reason
BTIG
Mark Massaro
Price Target
$96 -> $105
2025-11-25
maintain
Buy
Reason
BTIG analyst Mark Massaro raised the firm's price target on Tempus AI to $105 from $96 and keeps a Buy rating on the shares after meeting with its management team. Tempus AI outlined several durable growth drivers, namely that its data/pharma business is robust and diversified, Ambry's growth has tracked ahead of its deal model and is expected to grow over 20%, with rare disease testing as a complementary growth driver, and that its algo business might be a sleeper and could deliver over 80% gross margins with time, the analyst tells investors in a research note.
Morgan Stanley
NULL -> Overweight
upgrade
$68 -> $80
2025-11-11
Reason
Morgan Stanley
Price Target
$68 -> $80
2025-11-11
upgrade
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Tempus AI to $80 from $68 and keeps an Overweight rating on the shares.
Piper Sandler
Neutral
downgrade
$105 -> $80
2025-11-11
Reason
Piper Sandler
Price Target
$105 -> $80
2025-11-11
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Tempus AI to $80 from $105 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.
H.C. Wainwright
Yi Chen
Buy
downgrade
$98 -> $89
2025-11-07
Reason
H.C. Wainwright
Yi Chen
Price Target
$98 -> $89
2025-11-07
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Tempus AI to $89 from $98 and keeps a Buy rating on the shares post the Q3 report. The firm expects Tempus AI's sales growth in 2026 "to be healthy" at above 20%, but significantly less than the rate in 2025.
See All Ratings
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors led BTIG to reaffirm a Buy rating for Tempus AI?
Why has institutional ownership of Tempus AI increased significantly this quarter?
Will Tempus AI's stock price reach BTIG's target of $105 within a year?
How might the bullish put/call ratio impact Tempus AI's stock performance?